EC Neurology

Literature Review Article Volume 7 Issue 3 - 2017

Parkinson’s Disease and Drug Abuse

Kaushalendra Tripathi 1* and Richa Tripathi 2

1 Department of Neurology/Internal Medicine, Smt NHL Medical Municipal College, India
2 Department of Neurology , Emory University Atlanta Georgia, USA

*Corresponding Author: Kaushalendra Mani Tripathi, Department of Neurology/Internal Medicine, Smt NHL Medical Municipal College, India.
Received: July 17, 2017; Published: July 26, 2017



Background: Parkinson’s disease is described as hypokinetic symptoms with cardinal features such as tremors, bradykinesia, gait difficulties as well as cognitive problems. Much research has been done with regards to drugs of abuse such as opiates, amphet- amines, cocaine as well as therapeutic drugs causing this disease

Objectives: To provide a brief literature review in context to different reports with Parkinson’s and drug abuse and understand the implications of drugs on basal ganglia circuitry.

Methods: I present different reports collected of different drug interactions along with their studies, in an attempt to assimilate all the results and come to a conclusion.

Results: Use of drugs such as heroin, Methcathinone, inhalants, amphetamines, cocaine as well as therapeutic drugs such as pro- kinetic and SSRIs may predispose persons to Parkinson’s disease though NSAIDs have no such association.

Conclusions: Effect of such drugs in causing Parkinson’s should be discussed with patients on a clinical basis especially in the con- text of drug abuse.

Keywords: Parkinson’s; Drugs of Abuse

  1. Alexander G. “Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder”. Dialogues in Clinical Neuroscience 6.3 (2004): 259-280.
  2. Shin HW and Chung SJ. “Drug-Induced Parkinsonism”. (2012).
  3. Adinoff B. “Neurobiologic Processes in Drug Reward and Addiction”. Harvard Review of Psychiatry 12.6 (2004): 305-320.
  4. Johnson SW and North RA. “Opioids excite dopamine neurons by hyperpolarization of local interneurons”. Journal of Neuroscience 12.2 (1992): 483-488.
  5. William A., et al. “Rewarding Actions of Phencyclidine and Related Drugs in Nucleus”. The Journal of Neuroscience 16.9 (1996): 3112-3122.
  6. Solinas M., et al. “Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens”. Journal of Neuroscience 22.15 (2002): 6321-6324.
  7. Gramage E and Herradón G. “Connecting Parkinson’s disease and drug addiction: common players reveal unexpected disease connections and novel therapeutic approaches”. Current Pharmaceutical Design 17.5 (2011): 449-461.
  8. N Granado., et al. “Methamphetamine and Parkinson’s Disease”. Parkinson’s Disease (2013), Article ID 308052.
  9. LS Seiden and KE Sabol. “Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction”. NIDA Research Monograph 163 (1996): 251-276.
  10. ’Suilleabhain P and Giller C. “Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs”. Movement Disorders 18.11 (2003): 1378-1381.
  11. Mintzer S., et al. “Parkinsonism after taking ecstasy”. The New England Journal of Medicine 340.18 (1999): 1443.
  12. Kuniyoshi SM and Jankovic J. “MDMA and Parkinsonism”. The New England Journal of Medicine 349.1 (2003): 96-97.
  13. Kish SJ. “What is the evidence that Ecstasy (MDMA) can cause Parkinson’s disease?”. Movement Disorders 18.11 (2003): 1219-1223.
  14. Jerome L., et al. “Ecstasy use-Parkinson’s disease link tenuous”. Movement Disorders 19.11 (2004): 1386.
  15. Morton J. “Ecstasy: pharmacology and neurotoxicity”. Current Opinion in Pharmacology 5.1 (2005): 79-86.
  16. Bauer LO. “Resting hand tremor in abstinent cocaine-dependent, alcohol-dependent, and polydrug-dependent patients”. Alcoholism: Clinical and Experimental Research 20.7 (1996): 1196-1201.
  17. Di Rocco A., et al. “Inhaled cocaine used to relieve “off” periods in patients with Parkinson disease and unpredictable motor fluctuations: a report of 2 cases”. Journal of Clinical Psychopharmacology 26.6 (2006): 689-690.
  18. Sikk K., et al. “Irreversible motor impairment in young addicts--ephedrone, manganism or both?”. Acta Neurologica Scandinavica 115.6 (2007): 385-389.
  19. Stepens A., et al. “A Parkinsonian syndrome in methcathinone users and the role of manganese”. The New England Journal of Medicine 358.10 (2008): 1009-1017.
  20. Heales S., et al. “Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency”. Movement Disorders 19.10 (2004): 1248-1251.
  21. Offiah C and Hall E. “Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy”. Clinical Radiology 63.2 (2008): 146-152.
  22. Kriegstein AR., et al. “Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (“chasing the dragon”)”. Neurology 53.8 (1999): 1765-1773.
  23. Hageman G., et al. “Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure”. Journal of Neurology 246.3 (1999): 198-206.
  24. Matzler W., et al. “Acute parkinsonism with corresponding lesions in the basal ganglia after heroin abuse”. Neurology 68.6 (2007): 414.
  25. Caligiuri MP and Buitenhuys C. “Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?”. Neuropsychopharmacology 30.12 (2005): 2125-2134.
  26. Moszczynska A., et al. “Why is parkinsonism not a feature of human methamphetamine users?”. Brain 127 (2004): 363-370.
  27. Guilarte TR. “Is methamphetamine abuse a risk factor in Parkinsonism?”. Neurotoxicology 22.6 (2001): 725-731.
  28. Weintraub D., et al. “Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients”. Archives of neurology 67.5 (2010): 589-595.
  29. Wilson JM., et al. “Striatal dopamine nerve terminal markers in human, chronic methamphetamine users”. Nature Medicine 2.6 (1996): 699-703.
  30. Johanson CE., et al. “Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers”. Psychopharmacology (Berl) 185.3 (2006): 327-338.
  31. Boileau I., et al. “Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker?”. Journal of Neuroscience 28.39 (2008):9850-9856.
  32. Desai RI and Bergman J. “Drug discrimination in methamphetamine-trained rats: effects of cholinergic nicotinic compounds”. Journal of Pharmacology and Experimental Therapeutics 335.3 (2010): 807-816.
  33. Weinberger AH and Sofuoglu M. “The impact of cigarette smoking on stimulant addiction”. The American Journal of Drug and Alcohol Abuse 35.1 (2009):12-17.
  34. Hernán MA., et al. “A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease”. Annals of Neurology 52.3 (2002): 276-284.
  35. Christine CW., et al. “Parkinsonism in patients with a history of amphetamine exposure”. Movement Disorders 25.2 (2010): 228-231.
  36. García-Ruiz PJ., et al. “Calcium channel blocker-induced parkinsonism: clinical features and comparisons with Parkinson’s disease”. Parkinsonism and Related Disorders 4.4 (1998): 211-214.
  37. Martí-Massó JF and Poza JJ. “Cinnarizine-induced parkinsonism: ten years later”. Movement Disorders 13.3 (1998): 453-456.
  38. Negrotti A and Calzetti S. “A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism”. Movement Disorders 12.1 (1997): 107-110.
  39. Takada M., et al. “Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons”. Brain Research 590 (1992): 311-315.
  40. Hardie RJ and Lees AJ. “Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa”. Journal of Neurology, Neurosurgery, and Psychiatry 51.6 (1988): 850-854.
  41. Shin HW., et al. “Levosulpiride-induced movement disorders”. Movement Disorders 24.15 (2009): 2249-2253.
  42. Hassin-Baer S., et al. “Clinical characteristics of neuroleptic-induced parkinsonism”. Journal of Neural Transmission 108.11 (2001): 1299-1308.
  43. Miller LG and Jankovic J. “Metoclopramide-induced movement disorders. Clinical findings with a review of the literature”. Archives of Internal Medicine 149.11 (1989): 2486-2492.
  44. Kenney C., et al. “Metoclopramide, an increasingly recognized cause of tardive dyskinesia”. The Journal of Clinical Pharmacology 48.3 (2008): 379-384.
  45. Sethi KD., et al. “Metoclopramide-induced parkinsonism”. The Southern Medical Journal 82.12 (1989): 1581-1582.
  46. Hall RA., et al. “Neurotoxic reactions resulting from chlorpromazine administration”. The Journal of the American Medical Association 161.3 (1956): 214-218.
  47. Shanon J., et al. “An interesting reaction to a tranquilizer: tonic seizures with perphenazine (trilafon)”. The American Journal of Psychiatry 114.6 (1957): 556.
  48. Christian CD and Paulson G. “Severe motility disturbance after small doses of prochlorperazine”. The New England Journal of Medicine 259 (1958): 828-830.
  49. Ossowska K. “Neuronal basis of neuroleptic-induced extrapyramidal side effects”. Polish Journal of Pharmacology 54 (2002): 299-312.
  50. Tarsy D., et al. “Effects of newer antipsychotics on extrapyramidal function”. CNS Drugs 16.1 (2002): 23-45.
  51. Kuroki T., et al. “Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis”. Progress in Brain Research 172 (2008): 199-212.
  52. Kapur S and Seeman P. “Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis”. The American Journal of Psychiatry 158.3 (2001): 360-369.
  53. Stahl SM. ““Hit-and-Run” actions at dopamine receptors, part 2: illustrating fast dissociation from dopamine receptors that typifies atypical antipsychotics”. Journal of Clinical Psychiatry 62.10 (2001): 747-748.
  54. enito-León J., et al. “Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain”. Movement Disorders 18 (2003): 267-274.
  55. Wenning GK., et al. “Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study”. Lancet Neurology 4.12 (2005): 815-820.
  56. Barbosa MT., et al. “Parkinsonism and Parkinson’s disease in the elderly: a community-based survey in Brazil (the Bambuí study)”. Movement Disorders 21.6 (2006): 800-808.
  57. Bedard P., et al. “Oestrogens and extrapyramidal system”. Lancet 2 (1977): 1367-1368.
  58. Callaghan RC., et al. “Incidence of Parkinson’s disease among hospital patients with methamphetamine-use disorders”. Movement Disorders 25.14 (2010): 2333-2339.
  59. SJ Kish., et al. “Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications”. The New England Journal of Medicine 318.14 (1988): 876-880.
  60. Garwood ER., et al. “Amphetamine exposure is elevated in Parkinson’s disease”. Neurotoxicology 27.6 (2006): 1003-1006.

Kaushalendra Tripathi and Richa Tripathi. “Parkinson’s Disease and Drug Abuse”. EC Neurology  7.3 (2017): 117-127.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net